News

Morepen gets regulatory clearance for fatty liver drug development
Morepen Laboratories gains CDSCO approval for Resmetirom bioequivalence studies, positioning the company for global NASH ...
Morepen receives CDSCO nod to conduct BE studies for Resmetirom
Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and ...
EquityBulls6h
Morepen to Launch Resmetirom - a New Drug for Fatty Liver
Morepen Laboratories Ltd. has got clearance from Subject Expert Committee of CDSCO to conduct Bioequivalence studies for ...
TMCnet14h
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
Zurich (Switzerland), - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced ...